# KEY WORD INDEX


**Alloreactive T cells**
HLA-DRβ; Synthetic peptides; Alloresponse; Class II MHC (Ulrich, R. G., 285)

**Alloresponse**
HLA-DRβ; Alloreactive T cells; Synthetic peptides; Class II MHC (Ulrich, R. G., 285)

**Anti-*T. cruzi* IgG**
*Trypanosoma cruzi*; Clearance; C3 depletion (Mota, I., 223)

**Anti-cardiolipin anbitody**
Anti-poly (ADP-ribose) antibody; Systemic lupus erythematosus; Pregnancy (Kanai, Y., 217)

**Anti-chondrocyte T cell clones**
Chondrocyte antigens; Autoimmune arthritis; Mixed lymphocyte-chondrocyte reaction; Cytotoxicity; Anti-chondrocyte monoclonal antibodies (Lance, E. M., 63)

**Anti-chondrocyte monoclonal antibodies**
Chondrocyte antigens; Autoimmune arthritis; Mixed lymphocyte-chondrocyte reaction; Cytotoxicity; Anti-chondrocyte T cell clones (Lance, E. M., 63)

**Anti-poly (ADP-ribose) antibody**
Anti-cardiolipin antibody; Systemic lupus erythematosus; Pregnancy (Kanai, Y., 217)

**Antibrain antibodies**
Neuroimmunomodulation; Psychoneuroimmunology; Neurotransmitters; Stress; Behavioral immunology (Jankovič, B. D., 101)

**Antigen**
Theiler's murine encephalomyelitis virus; Immune response; Specificity; T cell; Spleen (Scheu, A.-K., 171)

**Articular chondrocytes**
Interleukin 1; Fibroblast growth factor; Colony formation (Iwamoto, M., 153)

**Autoantibody**
Systemic lupus erythematosus (SLE); Myeloid cells; Differentiation; c-myc; Epstein-Barr virus nuclear antigen (EBNA) (Kitagawa, H., 227)

**Autoimmune arthritis**
Chondrocyte antigens; Mixed lymphocyte-chondrocyte reaction; Cytotoxicity; Anti-chondrocyte monoclonal antibodies; Anti-chondrocyte T cell clones (Lance, E. M., 63)

**Autoimmune diabetes**
T cell dialysate; Inducer factor; Suppressor factor; Transfer factor (Lawrence, H. S., 75)

**B cell activation**
Complement; CR1; CR2 (Fingeroth, J. D., 291)

**B cell tolerance**
T cell tolerance; HLA; Neonatal tolerance; (Kidney) transplantation (Van Rood, J. J., 51)

**Behavioral immunology**
Neuroimmunomodulation; Psychoneuroimmunology; Neurotransmitters; Antibrain antibodies; Stress (Jankovič, B. D., 101)

**Binding affinity**
Monoclonal antibody; IgA subclasses; Secretory IgA (Reimer, C. B., 209)

**Blood transfusion**
Histocompatibility antigens; Renal transplantation; Cross-matching; Tissue typing; HLA system; Cyclosporine (Morris, P. J., 25)

**Brain neocortex modulation**
IL-2; Immunoregulation (Neveu, P. J., 307)

**C3**
Complement; CR2 (Yefenof, E., 303)

**C3 depletion**
*Trypanosoma cruzi*; Clearance; Anti-*T. cruzi* IgG (Mota, I., 223)

**C3b**
Complement receptor; IL-2 receptor; T cell; IL-2 (Bartók, I., 131)

**CD1 antigens**
Hepatitis B; Hepatitis B surface antigen (Roisman, F. R., 139)

**CD23**
Germinal center; IgD (Nahm, M. H., 201)

**CD45**
H-Y; 3-cell-type cluster; Thy 1; Skin graft (Mitchison, N. A., 15)

**CR1**
B cell activation; Complement; CR2 (Fingeroth, J. D., 291)

**CR2**
B cell activation; Complement; CR1 (Fingeroth, J. D., 291)

**CR2**
Complement; C3 (Yefenof, E., 303)

**Candida association**
Tuftsin; Peritoneal macrophages; Superoxide production (Kain, Z., 257)

**Cell differentiation**
Thymus gland; Rosette formation; Density gradient centrifugation; Guinea pig (Sandberg, G., 249)

**3-cell-type cluster**
H-Y; Thy 1; CD45; Skin graft (Mitchison, N. A., 15)

**Cellular chimerism**
Tolerance; Graft-versus-host disease; T lymphocyte depletion; Immunological maturation; Haemopoietic stem cells; Cynomolgus monkey (Brent, L., 55)

**Cellular mediated immune system**
γ-IFN; PHA; Neopterin (Barak, M., 317)

**Chimaeric proteins**
Soluble CD3 (Tunnacliffe, A., 243)

**Chondrocyte antigens**
Autoimmune arthritis; Mixed lymphocyte-chondrocyte reaction; Cytotoxicity; Anti-chondrocyte monoclonal antibodies; Anti-chondrocyte T cell clones (Lance, E. M., 63)
**Circular DNA**
Splenocytes; IgH; D-J joining (Toda, M., 311)
**Class II MHC**
HLA-DR$\beta$; Alloreactive T cells; Synthetic peptides; Alloresponse (Ulrich, R.G., 285)
**Clearance**
*Trypanosoma cruzi*; C3 depletion; Anti-*T. cruzi* IgG (Mota, I., 223)
**Clinical transplantation**
Medawar, P. B.; Scientific Method; Immunological tolerance (Hamilton, D., 9)
**Colony formation**
Interleukin 1; Fibroblast growth factor; Articular chondrocytes (Iwamoto, M., 153)
**Complement receptor**
IL-2 receptor; T cell; C3b; IL-2 (Bartók, I., 131)
**Complement**
B cell activation; CR1; CR2 (Fingeroth, J. D., 291)
**Complement**
C3; CR2 (Yefenof, E., 303)
**Cross-matching**
Histocompatibility antigens; Renal transplantation; Tissue typing; HLA system; Cyclosporine; Blood transfusion (Morris, P. J., 25)
**Cross-matching by flow cytometry**
Human kidney transplants; Cyclosporine; Preformed antibodies; Survival rates; Effect of ABDR compatibility (Terasaki, P. I., 33)
**Cyclosporine**
Histocompatibility antigens; Renal transplantation; Cross-matching; Tissue typing; HLA system; Blood transfusion (Morris, P. J., 25)
**Cyclosporine**
Human kidney transplants; Preformed antibodies; Survival rates; Cross-matching by flow cytometry; Effect of ABDR compatibility (Terasaki, P. I., 33)
**Cynomolgus monkey**
Tolerance; Cellular chimerism; Graft-versus-host disease; T lymphocyte depletion; Immunological maturation; Haemopoietic stem cells (Brent, L., 55)
**Cytotoxicity**
Chondrocyte antigens; Autoimmune arthritis; Mixed lymphocyte-chondrocyte reaction; Anti-chondrocyte monoclonal antibodies; Anti-chondrocyte T cell clones (Lance, E. M., 63)

**D-J joining**
Splenocytes; Circular DNA; IgH (Toda, M., 311)
**Density gradient centrifugation**
Thymus gland; Cell differentiation; Rosette formation; Guinea pig (Sandberg, G., 249)
**Differentiation**
LCA; Thymus (Pilarski, L. M., 187)
**Differentiation**
Systemic lupus erythematosus (SLE); Myeloid cells; c-myc; Autoantibody; Epstein-Barr virus nuclear antigen (EBNA) (Kitagawa, H., 227)

**Effect of ABDR compatibility**
Human kidney transplants; Cyclosporine; Preformed antibodies; Survival rates; Cross-matching by flow cytometry (Terasaki, P. I., 33)
**Epstein-Barr virus nuclear antigen (EBNA)**
Systemic lupus erythematosus (SLE); Myeloid cells; Differentiation; c-myc; Autoantibody (Kitagawa, H., 227)

**Fce receptor (CD23)**
Interleukin-4 (IL-4); Leu-M3 antigen (CD14) (Noma, T., 323)
**Fibroblast growth factor**
Interleukin 1; Articular chondrocytes; Colony formation (Iwamoto, M., 153)

**Germinal center**
CD23; IgD (Nahm, M. H., 201)
**Graft-versus-host disease**
Tolerance; Cellular chimerism; T lymphocyte depletion; Immunological maturation; Haemopoietic stem cells; Cynomolgus monkey (Brent, L., 55)
**Guinea pig**
Thymus gland; Cell differentiation; Rosette formation; Density gradient centrifugtion (Sandberg, G., 249)

**H-Y**
3-cell-type cluster; Thy 1; CD45; Skin graft (Mitchison, N. A., 15)
**HLA**
B cell tolerance; T cell tolerance; Neonatal tolerance; (Kidney) transplantation (Van Rood, J. J., 51)
**HLA system**
Histocompatibility antigens; Renal transplantation; Cross-matching; Tissue typing; Cyclosporine; Blood transfusion (Morris, P. J., 25)
**HLA-DR$\beta$**
Alloreactive T cells; Synthetic peptides; Alloresponse; Class II MHC (Ulrich, R. G., 285)
**Haemopoietic stem cells**
Tolerance; Cellular chimerism; Graft-versus-host disease; T lymphocyte depletion; Immunological maturation; Cynomolgus monkey (Brent, L., 55)
**Helper T cells**
Interleukins; Immune regulation (Yokoyama, A., 119)
**Hepatitis B**
CD1 antigens; Hepatitis B surface antigen (Roisman, F. R., 139)
**Hepatitis B surface antigen**
Hepatitis B; CD1 antigens (Roisman, F.R., 139)
**Histocompatibility antigens**
Renal transplantation; Cross-matching; tissue typing; HLA system; Cyclosporine; Blood transfusion (Morris, P. J., 25)
**Human kidney transplants**
Cyclosporine; Preformed antibodies; Survival rates; Cross-matching by flow cytometry; Effect of ABDR compatibility (Terasaki, P. I., 33)

**IL-2**
Complement receptor; IL-2 receptor; T cell; C3b (Bartók, I., 131)
**IL-2**
Brain neocortex modulation; Immunoregulation (Neveu, P. J., 307)
**IL-2 receptor**
Complement receptor; T cell; C3b; IL-2 (Bartók, I., 131)
**IL-6/BSF-2/HGF, OK-432**
(Fukui, H., 127)
**γ-IFN**
PHA; Cellular mediated immune system; Neopterin (Barak, M., 317)
**IgA subclasses**
Binding affinity; Monoclonal antibody; Secretory IgA (Reimer, C. B., 209)
**IgD**
Germinal center; CD23 (Nahm, M. H., 201)
**IgH**
Splenocytes; Circular DNA; D-J joining (Toda, M., 311)
**Immune regulation**
Helper T cells; Interleukins (Yokoyama, A., 119)
**Immune response**
Theiler's murine encephalomyelitis virus; Specificity; T cell; Spleen; Antigen (Scheu, A.-K., 171)
**Immunological tolerance**
Medawar, P. B.; Clinical transplantation; Scientific Method (Hamilton, D., 9)
**Immunological maturation**
Tolerance; Cellular chimerism; Graft-versus-host disease; T lymphocyte depletion; Haemopoietic stem cells; Cynomolgus monkey (Brent, L., 55)
**Immunoregulation**
IL-2; Brain neocortex modulation (Neveu, P. J., 307)
**Immunoregulation**
Transplantation immunity; Pregnancy; Trophoblast; Placental barrier (Billington, W. D., 45)
**Inducer factor**
T cell dialysate; Suppressor factor; Transfer factor; Autoimmune diabetes (Lawrence, H. S., 75)
**Interferon-beta2**
Tumor necrosis factor (alpha and beta); Lymphotoxin; Interleukin 1; Interleukin 6; 2-5A synthetase (Ruggiero, V., 165)
**Interferon gamma production**
Interleukin 2; Interleukin 4; Lymphocyte proliferation (Wagner, F., 237)
**Interleukin 1**
Fibroblast growth factor; Articular chondrocytes; Colony formation (Iwamoto, M., 153)
**Interleukin 1**
Tumor necrosis factor (alpha and beta); Lymphotoxin; Interferon-beta2; Interleukin 6; 2-5A synthetase (Ruggiero, V., 165)
**Interleukin 2**
Interferon gamma production; Interleukin 4; Lymphocyte proliferation (Wagner, F., 237)
**Interleukin 2**
LGL; Natural killer cells; NK cell augmentation (Savary, C. A., 145)
**Interleukin 4**
Interferon gamma production; Interleukin 2; Lymphocyte proliferation (Wagner, F., 237)
**Interleukin-4 (IL-4)**
Fce receptor (CD23); Leu-M3 antigen (CD14) (Noma, T., 323)
**Interleukin 6**
Neutrophil; Monocyte; Oxidative burst (Kharazmi, A., 177)
**Interleukin 6**
Tumor necrosis factor (alpha and beta); Lymphotoxin; Interleukin 1; Interferon-beta2; 2-5A synthetase (Ruggiero, V., 165)
**Interleukins**
Helper T cells; Immune regulation (Yokoyama, A., 119)

**(Kidney) transplantation**
B cell tolerance; T cell tolerance; HLA; Neonatal tolerance (Van Rood, J. J., 51)

**LCA**
Thymus; Differentiation (Pilarski, L. M., 187)
**LGL**
Interleukin 2; Natural killer cells; NK cell augmentation (Savary, C. A., 145)
**Leu-M3 antigen (CD14)**
Interleukin-4 (IL-4); Fce receptor (CD23) (Noma, T., 323)
**Lymphocyte proliferation**
Interferon gamma production; Interleukin 2; Interleukin 4 (Wagner, F., 237)
**Lymphotoxin**
Tumor necrosis (alpha and beta); Interleukin 1; Interferon-beta2; Interleukin 6; 2-5A synthetase (Ruggiero, V., 165)

**Medawar, P. B.**
Clinical transplantation; Scientific Method; Immunological tolerance (Hamilton, D., 9)
**Mixed lymphocyte-chondrocyte reaction**
Chondrocyte antigens; Autoimmune arthritis; Cytotoxicity; Anti-chondrocyte monoclonal antibodies; Anti-chondrocyte T cell clones (Lance, E. M., 63)
**Monoclonal antibody**
Binding affinity; IgA subclasses; Secretory IgA (Reimer, C. B., 209)
**Monocyte**
Interleukin 6; Neutrophil; Oxidative burst (Kharazmi, A., 177)
**c-myc**
Systemic lupus erythematosus (SLE); Myeloid cells; Differentiation; Autoantibody; Epstein-Barr virus nuclear antigen (EBNA) (Kitagawa, H., 227)
**Myeloid cells**
Systemic lupus erythematosus (SLE); Differentiation; c-myc; Autoantibody; Epstein-Barr virus nuclear antigen (EBNA) (Kitagawa, H., 227)

**NK cell augmentation**
LGL; Interleukin 2; Natural killer cells (Savary, C. A., 145)
**Natural killer cells**
LGL; Interleukin 2; NK cell augmentation (Savary, C. A., 145)
**Neonatal tolerance**
B cell tolerance; T cell tolerance; HLA; (Kidney) transplantation (Van Rood, J. J., 51)

**Neopterin**
γ-IFN; PHA; Cellular mediated immune system (Barak, M., 317)
**Neuroimmunomodulation**
Psychoneuroimmunology; Neurotransmitters; Antibrain antibodies; Stress; Behavioral immunology (Jankovič, B. D., 101)
**Neurotransmitters**
Neuroimmunomodulation; Psychoneuroimmunology; Antibrain antibodies; Stress; Behavioral immunology (Jankovič, B. D., 101)
**Neutrophil**
Interleukin 6; Monocyte; Oxidative burst (Kharazmi, A., 177)

**Oxidative burst**
Interleukin 6; Neutrophil; Monocyte (Kharazmi, A., 177)

**PHA**
γ-IFN; Cellular mediated immune system; Neopterin (Barak, M., 317)
**Peritoneal macrophages**
Tuftsin; Superoxide production; Candida association (Kain, Z., 257)
**Placental barrier**
Transplantation immunity; Pregnancy; Immunoregulation; Trophoblast (Billington, W. D., 45)
**Preformed antibodies**
Human kidney transplants; Cyclosporine; Survival rates; Cross-matching by flow cytometry; Effect of ABDR compatibility (Terasaki, P. I., 33)
**Pregnancy**
Anti-poly (ADP-ribose) antibody; Anti-cardiolipin antibody; Systemic lupus erythematosus (Kanai, Y., 217)
**Pregnancy**
Transplantation immunity; Immunoregulation; Trophoblast; Placental barrier (Billington, W. D., 45)
**Psychoneuroimmunology**
Neuroimmunomodulation; Neurotransmitters; Antibrain antibodies; Stress; Behavioral immunology (Jankovič, B. D., 101)

**Renal transplantation**
Histocompatibility antigens; Cross-matching; Tissue typing; HLA system; Cyclosporine; Blood transfusion (Morris, P. J., 25)
**Rosette formation**
Thymus gland; Cell differentiation; Density gradient centrifugation; Guinea pig (Sandberg, G., 249)

**Scientific Method**
Medawar, P. B.; Clinical transplantation; Immunological tolerance (Hamilton, D., 9)
**Secretory IgA**
Binding affinity; Monoclonal antibody; IgA subclasses (Reimer, C. B., 209)
**Skin graft**
H-Y; 3-cell-type cluster; Thy 1; CD45 (Mitchison, N. A., 15)
**Soluble CD3**
Chimaeric proteins (Tunnacliffe, A., 243)
**Specificity**
Theiler's murine encephalomyelitis virus; Immune response; T cell; Spleen; Antigen (Scheu, A.-K., 171)
**Spleen**
Theiler's murine encephalomyelitis virus; Immune response; Specificity; T cell; Antigen (Scheu, A.-K., 171)
**Splenocytes**
Circular DNA; IgH; D-J joining (Toda, M., 311)
**Stress**
Neuroimmunomodulation; Psychoneuroimmunology; Neurotransmitters; Antibrain antibodies; Behavioral immunology (Jankovič, B. D., 101)
**Superoxide production**
Tuftsin; Peritoneal macrophages; Candida association (Kain, Z., 257)
**Suppressor factor**
T cell dialysate; Inducer factor; Transfer factor; Autoimmune diabetes (Lawrence, H. S., 75)
**Survival rates**
Human kidney transplants; Cyclosporine; Preformed antibodies; Cross-matching by flow cytometry; Effect of ABDR compatibility (Terasaki, P. I., 33)
**2-5A synthetase**
Tumor necrosis factor (alpha and beta); Lymphotoxin; Interleukin 1; Interferon-beta2; Interleukin 6 (Ruggiero, V., 165)
**Synthetic peptides**
HLA-DRβ; Alloreactive T cells; Alloresponse; Class II MHC (Ulrich, R. G., 285)
**Systemic lupus erythematosus**
Anti-poly (ADP-ribose) antibody; Anti-cardiolipin antibody; Pregnancy (Kanai, Y., 217)
**Systemic lupus erythematosus (SLE)**
Myeloid cells; Differentiation; c-myc; Autoantibody; Epstein-Barr virus nuclear antigen (EBNA) (Kitagawa, H., 227)

**T cell**
Complement receptor; IL-2 receptor; C3b; IL-2 (Bartók, I., 131)
**T cell**
Theiler's murine encephalomyelitis virus; Immune response; Specificity; Spleen; Antigen (Scheu, A.-K., 171)
**T cell dialysate**
Inducer factor; Suppressor factor; Transfer factor; Autoimmune diabetes (Lawrence, H. S., 75)
**T cell tolerance**
B cell tolerance; HLA; Neonatal tolerance; (Kidney) transplantation (Van Rood, J. J., 51)
**T lymphocyte depletion**
Tolerance; Cellular chimerism; Graft-versus-host disease; Immunological maturation; Haemopoietic stem cells; Cynomolgus monkey (Brent, L., 55)
**Theiler's murine encephalomyelitis virus**
Immune response; Specificity; T cell; Spleen; Antigen (Scheu, A.-K., 171)
**Thy 1**
H-Y; 3-cell-type cluster; CD45; Skin graft (Mitchison, N. A., 15)
**Thymus**
LCA; Differentiation (Pilarski, L. M., 187)
**Thymus gland**
Cell differentiation; Rosette formation; Density gradient centrifugation; Guinea pig (Sandberg, G., 249)
**Tissue typing**
Histocompatibility antigens; Renal transplantation; Cross-

matching; HLA system; Cyclosporine; Blood transfusion (Morris, P. J., 25)

**Tolerance**
Cellular chimerism; Graft-versus-host disease; T lymphocyte depletion; Immunological maturation; Haemopoietic stem cells; Cynomolgus monkey (Brent, L., 55)

**Transfer factor**
T cell dialysate; Inducer factor; Suppressor factor; Autoimmune diabetes (Lawrence, H. S., 75)

**Transplantation immunity**
Pregnancy; Immunoregulation; Trophoblast; Placental barrier (Billington, W. D., 45)

**Trophoblast**
Transplantation immunity; Pregnancy; Immunoregulation; Placental barrier (Billington, W. D., 45)

***Trypanosoma cruzi***
Clearance; C3 depletion; Anti-*T. cruzi* IgG (Mota, I., 223)

**Tuftsin**
Peritoneal macrophages; Superoxide production; Candida association (Kain, Z., 257)

**Tumor necrosis factor (alpha and beta)**
Lymphotoxin; Interleukin 1; Interferon-beta2; Interleukin 6; 2-5A synthetase (Ruggiero, V., 165)

# AUTHOR INDEX


**Al-Imara, L.**, see Brent, L., 55
**Alkan, M.**, see Kain, Z., 257
**Aloisio, C. H.**, see Reimer, C. B., 209
**Ambrosino, D. M.**, see Fingeroth, J. D., 291
**Antonelli, G.**, see Ruggiero, V., 165
**Arnon, R.**, see McEwen, J., 157
**Atassi, M. Zouhair**, see Ulrich, R. G. 285
**Aucouturier, P.**, Lacombe, C., Bremard-Oury, C., Lebranchu, Y., Griscelli, C. and Preud'homme, J-L., Normal IgG subclass levels in the hyperIgE syndrome (Letter to the Editor), 329

**Bach, F. H.**, Toward an understanding of the basis of alloantigen recognition, 21
**Barak, M.**, Merzbach, D. and Gruener, N., The effect of immunomodulators on PHA or γ-IFN induced release of neopterin from purified macrophages and peripheral blood mononuclear cells, 317
**Barnéoud, P.**, see Neveu, P. J., 307
**Bartók, I.**, Erdei, A., Mouzaki, A., Osawa, H., Szölösi, J., Eigentler, A., Diamantstein, T., Dierich, M. P. and Gergely, J., Interaction between C3 and IL-2; inhibition of C3b binding to CR1 by IL-2, 131
**Batchelor, J. R.**, see Brent, L., 81
**Bendtzen, K.**, see Kharazmi, A., 177
**Beverley, P. C. L.**, CD45 and the thymus (Comments on minireview by Pilarski and Deans), 199
**Billingham, R. E.**, see Calne, R. Y., 91
**Billington, W. D.**, 'The foetus, quâ tissue homograft': an assessment of the possible mechanisms for its survival, 45
**Black, C. M.**, see Reimer, C. B., 209
**Borkowsky, W.**, see Lawrence, H. S., 75
**Bowen, M. B.**, see Nahm, M. H., 201
**Bremard-Oury, C.**, see Aucouturier, P., 329
**Brent, L.**, Batchelor, J. R., Calne, R. Y., Festenstein, H., Morris, P. J. and Woodruff, M. F. A., The role of immunology in the development of clinical transplantation, 81
**Brent, L.**, Linch, D. C., Rodeck, C. H., Nicolaides, K., DeGiorgi, L., Sherwood, R. A., Al-Imara, L., Mew, J. and Socha, W., On the feasibility of inducing tolerance in man: a study in the cynomolgus monkey, 55
**Brent, L.**, see Calne, R. Y. 91
**Bubeník, J.**, Local immunotherapy of cancer with interleukin 2 (Minireview), 267

**Calne, R. Y.**, Billingham, R. E., Brent, L., Taylor, R. M. R. and Medawar, J., Speeches, Memorial Dinner, Sir Peter Medawar Memorial Symposium, Monday evening, 5th December, 1988, 91
**Calne, R. Y.**, see Brent, L., 81
**Cecka, M.**, see Terasaki, P. I., 33
**Chaimovitz, C.**, see Kain, Z., 257
**Cicciarelli, J.**, see Terasaki, P. I., 33
**Claas, F. H. F.**, see Van Rood, J. J., 51
**Conciatori, G.**, see Ruggiero, V., 165
**Cuesta, A.**, see Scheu, A.-K., 171

**Dancygier, H.**, see Wagner, F., 237
**DeGiorgi, L.**, see Brent, L., 55
**Deans, J. P.**, see Pilarski, L. M., 187
**Diamantstein, T.**, see Bartók, I., 131
**Dianzani, F.**, see Ruggiero, V., 165
**Dierich, M. P.**, see Bartók, I., 131
**Dunne, D. E.**, see Yokoyama, A., 119

**Eigentler, A.**, see Bartók, I., 131
**Erdei, A.**, see Bartók, I., 131
**Evavold, B.**, see Yokoyama, A., 119

**Fainboim, H.**, see Roisman, F. R., 139
**Fainboim, L.**, see Roisman, F. R., 139
**Festenstein, H.**, see Brent, L., 81
**Fingeroth, J. D.**, Heath, M. E. and Ambrosino, D. M., Proliferation of resting B cells is modulated by CR2 and CR1, 291
**Fisher, N.**, see Wagner, F., 237
**Fridkin, M.**, see Kain, Z., 257
**Fukui, H.**, Koishihara, Y., Nagamuta, M., Mizutani, Y. and Uchida, A., Production of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432, 127

**Gentile, M.**, see Ruggiero, V., 165
**Gergely, J.**, see Bartók, I., 131
**Gowans, J. L.**, Peter Medawar: his life and work, 5
**Griscelli, C.**, see Aucouturier, P., 329
**Gruener, N.**, see Barak, M., 317

**Hama, K.**, see Noma, T., 323
**Hamilton, D.**, Peter Medawar and clinical transplantation, 9
**Harari, I.**, see McEwen, J., 157
**Hart, R.**, see Wagner, F., 237
**Heath, M. E.**, see Fingeroth, J. D., 291
**Hirama, T.**, see Toda, M., 311
**Honjo, T.**, see Noma, T., 323
**Hoshino, T.**, see Kitagawa, H., 227

**Isonishi, S.**, see Kanai, Y., 217
**Iwaki, Y.**, see Terasaki, P. I., 33

**Iwamoto, M.**, Koike, T., Nakashima, K., Sato, K. and Kato, Y., Interleukin 1: a regulator of chondrocyte proliferation, 153

**Janković, B. D.**, Neuroimmunomodulation: facts and dilemmas, 101

**Kain, Z.**, Alkan, M., Chaimovitz, C., Segal, S., Fridkin, M. and Levy, R., Human peritoneal macrophage activity is increased by tuftsin, 257

**Kanai, Y.**, Isonishi, S. and Terashima, Y., Antibody to poly(ADP-ribose) is an indicator of obstetric complications in pregnant patients with systemic lupus erythematosus, 217

**Karjalainen, K.**, see Tunnacliffe, A., 243

**Kato, Y.**, see Iwamoto, M., 153

**Kelley, K. W.**, see Neveu, P. J., 307

**Kharazmi, A.**, Nielsen, H., Rechnitzer, C. and Bendtzen, K., Interleukin 6 primes human neutrophil and monocyte oxidative burst response, 177

**Kitagawa, H.** and Hoshino, T., Detection of antibodies to the antigens involving differentiation of myeloid cells in sera from patients with systemic lupus erythematosus, 227

**Klein, E.**, see Yefenof, E., 303

**Klostergaard, J.**, see Savary, C. A., 145

**Koike, T.**, see Iwamoto, M., 153

**Koishihara, Y.**, see Fukui, H., 127

**Kölare, S.**, see Sandberg, G., 249

**Krissansen, G. W.**, see Tunnacliffe, A., 243

**Lacombe, C.**, see Aucouturier, P., 329

**Lance, E. M.**, Immunological reactivity towards chondrocytes in rat and man: relevance to autoimmune arthritis, 63

**Lawrence, H. S.** and Borkowsky, W., The nature and functions of inducer factor and suppressor factor in T cell dialysates, 75

**Le Moal, M. A.**, see Neveu, P. J., 307

**Lebranchu, Y.**, see Aucouturier, P., 329

**Leitner, M.**, see McEwen, J., 157

**Lersch, C.**, see Wagner, F., 237

**Levy, R.**, see Kain, Z., 257

**Linch, D. C.**, see Brent, L., 55

**Lotzová, E.**, see Savary, C. A., 145

**Lovering, E.**, see Simpson, E., 39

**Macke, K. A.**, see Nahm, M. H., 201

**McEwen, J.**, Leitner, M., Harari, I. and Arnon, R., Expression of Shiga toxin epitopes in *E. coli* immunological characterization, 157

**Medawar, J.**, see Calne, R. Y., 91

**Merzbach, D.**, see Barak, M., 317

**Mew, J.**, see Brent, L., 55

**Mickey, M. R.**, see Terasaki, P. I., 33

**Mitchison, N. A.**, T cells in transplantation immunity, 15

**Mizutani, Y.**, see Fukui, H., 127

**Morris, P. J.**, Histocompatibility antigens and transplantation: reflections over 20 years, 25

**Morris, P. J.**, see Brent, L., 81

**Mota, A.**, see Roisman, F. R., 139

**Mota, I.** and Umekita, L. F., The effect of C3 depletion on the clearance of *Trypanosoma cruzi* induced by IgG antibodies, 223

**Mouzaki, A.**, see Bartók, I., 131

**Nagamuta, M.**, see Fukui, H., 127

**Nahm, M. H.**, Takes, P. A., Bowen, M. B. and Macke, K. A., Subpopulations of B lymphocytes in germinal centers, II. A germinal center B cell subpopulation expresses sIgD and CD23, 201

**Nakakubo, H.**, see Noma, T., 323

**Nakashima, K.**, see Iwamoto, M., 153

**Neveu, P. J.**, Barnéoud, P., Vitiello, S., Kelley, K. W. and Le Moal, M. A., Brain neocortex modulation of mitogen-induced interleukin 2, but not interleukin 1, production, 307

**Nicolaides, K.**, see Brent, L., 55

**Nielsen, H.**, see Kharazmi, A., 177

**Nilsson, B.**, see Yefenof, E., 303

**Noma, T.**, Nakakubo, H., Hama, K. and Honjo, T., Multiple effects of human recombinant interleukin 4 on human myeloid monocyte cell lines, 323

**Olsson, C.**, see Tunnacliffe, A., 243

**Osawa, H.**, see Bartók, I., 131

**Phillips, D. J.**, see Reimer, C. B., 209

**Pilarski, L. M.** and Deans, J. P., Selective expression of CD45 isoforms and of maturation antigens during human thymocyte differentiation: observations and hypothesis (Minireview), 187

**Preud'homme, J-L.**, see Aucouturier, P., 329

**Quintans, J.**, see Yokoyama, A., 119

**Ramos, O. F.**, see Yefenof, E., 303

**Ramos, T.**, Interleukin 5 is a differentiation factor for cytotoxic T lymphocytes, 277

**Rechnitzer, C.**, see Kharazmi, A., 177

**Reimer, C. B.**, Phillips, D. J., Aloiso, C. H., Black, C. M. and Wells, T. W., Specificity and association constants of 33 monoclonal antibodies to human IgA epitopes, 209

**Rodeck, C. H.**, see Brent, L., 55

**Roisman, F. R.**, Salamone, M. del C., Mota, A., Fainboim, H. and Fainboim, L., Expression of CD1 antigens by peripheral blood mononuclear cells from heptatitis B patients, 139

**Rubio, N.**, see Scheu, A.-K., 171

**Ruggiero, V.**, Antonelli, G., Gentile, M., Conciatori, G. and Dianzani, F., Comparative study on the antiviral activity of tumor necrosis factor (TNF)-alpha, lymphotoxin/TNF-beta, and IL-1 in WISH cells, 165

**Salamone, M. del C.**, see Roisman, F. R. 139

**Sandberg, G.** and Kölare, S., Studies on thymocyte subpopulations in guinea pigs: in vivo differentiation of bromodeoxyuridine labelled cells, with special reference to rosette-forming ability, 249

**Sato, K.**, see Iwamoto, M., 153

**Savary, C. A.**, Lotzová, E. and Klostergaard, J., Interleu-

kin 2-activated large granular lymphocytes: cytotoxic efficiency and mechanism of killing of tumor cell lines, 145
**Scheu, A.-K.**, Cuesta, A. and Rubio, N., Characterization of the immune response to intracerebral inoculation of Theiler's murine encephalomyelitis virus: fine protein specificity of the splenic T cell and humoral antibody response, 171
**Segal, S.**, see Kain, Z., 257
**Sherwood, R. A.**, see Brent, L., 55
**Simpson, E.**, Tomonari, K. and Lovering, E., Minor transplantation antigens: their role in shaping the T cell repertoire, 39
**Socha, W.**, see Brent, L., 55
**Szölösi, J.**, see Bartók, I., 131

**Takes, P. A.**, see Nahm, M. H., 201
**Takeshita, S.**, see Toda, M., 311
**Taylor, R. M. R.**, see Calne, R. Y., 91
**Terasaki, P. I.**, Mickey, M. R., Cecka, M., Iwaki, Y. and Cicciarelli, J., Clinical kidney transplants, 1988, 33
**Terashima, Y.**, see Kanai, Y., 217
**Toda, M.**, Hirama, T., Takeshita, S. and Yamagishi, H., Excision products of immunoglobulin gene rearrangements, 311
**Tomonari, K.**, see Simpson, E., 39
**Traunecker, A.**, see Tunnacliffe, A., 243
**Tunnacliffe, A.**, Olsson, C., Traunecker, A., Krissansen, G. W. and Karjalainen, K., Production and secretion of recombinant soluble CD3 polypeptides by myeloma-derived transfectant clones, 243
**Taylor, R. M. R.**, Preface to Medawar Symposium Special Issue, 3

**Uchida, A.**, see Fukui, H., 127
**Ulrich, R. G.** and Zouhair Atassi, M., Alloreactive T cell recognition of the HLA-DR$\beta$ N-terminal polymorphic region, 285
**Umekita, L. F.**, see Mota, I., 223

**Vaag, J.**, The dilemmas of immunotherapy (Comments on Dr. Jan Bubeník's review), 275
**Van Leeuwen, A.**, see Van Rood, J. J., 51
**Van Rood, J. J.**, Zhang, L., Van Leeuwen, A. and Claas, F. H. J., Neonatal tolerance revisited, 51
**Vitiello, S.**, see Neveu, P. J., 307

**Wagner, F.**, Fisher, N., Lersch, C., Hart, R. and Dancygier, H., Interleukin 4 inhibits the interleukin 2-induced production of its functional antagonist, interferon gamma, 237
**Wells, T. W.**, see Reimer, C. B., 209
**Woodruff, M. F. A.**, see Brent, L., 81

**Yamagishi, H.**, see Toda, M., 311
**Yefenof, E.**, Ramos, O. F., Nilsson, B. and Klein, E., Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum, 303
**Yokoyama, A.**, Evavold, B., Dunne, D. E. and Quintans, J., Production of IL-2 and IFN by TH2 clones, 119

**Zhang, L.**, see Van Rood, J. J., 51
**Zouhair Atassi, M.**, see Ulrich, R. G., 285